Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma.

Publication

Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma.

Journal Paper/Review - Dec 15, 2022

Wang Jian, Weiss Tobias, Neidert Marian C, Toussaint Nora C, Naghavian Reza, Sellés Moreno Carla, Foege Magdalena, Tomas Ojer Paula, Medici Gioele, Jelcic Ivan, Schulz Daniel, Rushing Elisabeth, Dettwiler Susanne, Schrörs Barbara, Shin Joo Heon, McKay Ron, Wu Catherine J, Lutterotti Andreas, Sospedra Mireia, Moch Holger, Greiner Erich F, Bodenmiller Bernd, Regli Luca, Weller Michael, Roth Patrick, Martin Roland

Citation

Wang J, Weiss T, Neidert M, Toussaint N, Naghavian R, Sellés Moreno C, Foege M, Tomas Ojer P, Medici G, Jelcic I, Schulz D, Rushing E, Dettwiler S, Schrörs B, Shin J, McKay R, Wu C, Lutterotti A, Sospedra M, Moch H, Greiner E, Bodenmiller B, Regli L, Weller M, Roth P, Martin R. Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma. Clin Cancer Res 2022; 28:5368-5382.

Type

Journal Paper/Review (English)

Journal

Clin Cancer Res 2022; 28

Publication Date

Dec 15, 2022

Issn Electronic

1557-3265

Pages

5368-5382

Brief description/objective

The low mutational load of some cancers is considered one reason for the difficulty to develop effective tumor vaccines. To overcome this problem, we developed a strategy to design neopeptides through single amino acid mutations to enhance their immunogenicity.